Editas Medicine, headquartered in Cambridge, Massachusetts, specializes in genome editing technology and developed a proprietary CRISPR-based platform for transformative genomic medicines. Its lead program, reni-cel, aims to treat sickle cell disease and beta thalassemia.
Editas Medicine (EDIT) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Editas Medicine's actual EPS was -$0.55, missing the estimate of -$0.36 per share, resulting in a -51.18% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
